Equities analysts predict that NxStage Medical, Inc. (NASDAQ:NXTM) will announce $102.29 million in sales for the current fiscal quarter, according to Zacks. Three analysts have made estimates for NxStage Medical’s earnings, with estimates ranging from $100.90 million to $103.60 million. NxStage Medical posted sales of $91.95 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 11.2%. The firm is expected to report its next quarterly earnings report on Thursday, November 2nd.

On average, analysts expect that NxStage Medical will report full year sales of $102.29 million for the current financial year, with estimates ranging from $398.30 million to $402.90 million. For the next year, analysts expect that the business will report sales of $443.89 million per share, with estimates ranging from $435.90 million to $460.20 million. Zacks’ sales calculations are an average based on a survey of analysts that follow NxStage Medical.

NxStage Medical (NASDAQ:NXTM) last posted its earnings results on Monday, August 7th. The medical device company reported ($0.03) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.03). The company had revenue of $92.20 million for the quarter, compared to analysts’ expectations of $96.47 million. NxStage Medical had a negative return on equity of 2.43% and a negative net margin of 1.33%. The firm’s quarterly revenue was up .0% compared to the same quarter last year. During the same period last year, the business posted ($0.03) earnings per share.

NXTM has been the topic of a number of analyst reports. Craig Hallum initiated coverage on NxStage Medical in a research report on Tuesday, June 27th. They issued a “buy” rating and a $32.00 price target on the stock. BidaskClub upgraded NxStage Medical from a “hold” rating to a “buy” rating in a report on Friday, June 30th. Northland Securities restated a “hold” rating and set a $30.00 target price on shares of NxStage Medical in a report on Monday, August 7th. Canaccord Genuity cut NxStage Medical from a “buy” rating to a “hold” rating and set a $30.00 target price on the stock. in a report on Monday, August 7th. Finally, William Blair cut NxStage Medical from an “outperform” rating to a “market perform” rating in a report on Monday, August 7th. One research analyst has rated the stock with a sell rating and nine have given a hold rating to the company’s stock. NxStage Medical has a consensus rating of “Hold” and a consensus price target of $30.25.

In other news, President Joseph E. Turk, Jr. sold 1,000 shares of the company’s stock in a transaction on Wednesday, July 5th. The stock was sold at an average price of $25.19, for a total transaction of $25,190.00. Following the transaction, the president now owns 75,903 shares of the company’s stock, valued at $1,911,996.57. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Matthew W. Towse sold 4,300 shares of the company’s stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $24.16, for a total value of $103,888.00. Following the transaction, the senior vice president now directly owns 28,721 shares in the company, valued at approximately $693,899.36. The disclosure for this sale can be found here. Insiders have sold 50,400 shares of company stock worth $1,403,650 in the last 90 days. Company insiders own 4.70% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of NXTM. Russell Investments Group Ltd. lifted its stake in shares of NxStage Medical by 67.9% during the first quarter. Russell Investments Group Ltd. now owns 28,847 shares of the medical device company’s stock valued at $773,000 after acquiring an additional 11,668 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of NxStage Medical by 0.5% during the first quarter. Bank of New York Mellon Corp now owns 639,866 shares of the medical device company’s stock valued at $17,168,000 after acquiring an additional 2,914 shares during the period. UBS Asset Management Americas Inc. lifted its stake in shares of NxStage Medical by 148.4% during the first quarter. UBS Asset Management Americas Inc. now owns 32,532 shares of the medical device company’s stock valued at $873,000 after acquiring an additional 19,434 shares during the period. Karp Capital Management Corp acquired a new position in shares of NxStage Medical during the first quarter valued at $256,000. Finally, Parametric Portfolio Associates LLC lifted its stake in shares of NxStage Medical by 45.9% during the first quarter. Parametric Portfolio Associates LLC now owns 45,716 shares of the medical device company’s stock valued at $1,227,000 after acquiring an additional 14,384 shares during the period. 92.75% of the stock is currently owned by institutional investors and hedge funds.

Shares of NxStage Medical (NXTM) opened at 27.75 on Friday. The company’s 50 day moving average is $27.80 and its 200-day moving average is $25.85. NxStage Medical has a 52 week low of $20.45 and a 52 week high of $30.80. The company’s market capitalization is $1.83 billion.

COPYRIGHT VIOLATION WARNING: This story was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/09/22/nxstage-medical-inc-nxtm-expected-to-announce-quarterly-sales-of-102-29-million.html.

About NxStage Medical

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Get a free copy of the Zacks research report on NxStage Medical (NXTM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.